Dynavax Technologies Corporation (DVAX)
After hours:
| Previous Close | 11.82 |
| Open | 11.83 |
| Bid | 11.98 x 1300 |
| Ask | 12.01 x 600 |
| Day's Range | 11.79 - 12.06 |
| 52 Week Range | 10.48 - 15.15 |
| Volume | |
| Avg. Volume | 2,105,123 |
| Market Cap | 1.569B |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | 171.29 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
Dynavax Technologies said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve the expanded use of its hepatitis B vaccine in patients undergoing hemodialysis, citing insufficient safety and effectiveness data. The FDA, in its so-called "complete response letter", stated that the data was insufficient as a third-party clinical trial site operator had destroyed data source documents for about half of the subjects enrolled in the vaccine's trial, according to the company. Dynavax's vaccine, Heplisav-B, was first approved by the FDA in 2017, having been rejected twice before in 2013 and 2016 over unresolved safety concerns.
- Simply Wall St.
Analysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter Results
Dynavax Technologies Corporation ( NASDAQ:DVAX ) just released its latest first-quarter report and things are not...
- GuruFocus.com
Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...
Comprehensive Analysis of Dynavax's Financial Performance and Strategic Initiatives
